Abstract
The kynurenine pathway from tryptophan generates compounds which can act on glutamate receptors in peripheral tissues or modulate free radical activity. We have measured the concentrations of several of these compounds in the plasma of patients with rheumatoid arthritis (RA) and osteoporosis (OP) before treatment with drugs and then at monthly intervals for 6 months during treatment. Kynurenine analysis was performed by HPLC. Compared with healthy controls, RA patients showed significantly decreased baseline levels of tryptophan, 3-hydroxykynurenine and 3-hydroxyanthranilic acid and increased levels of kynurenine and xanthurenic acid, while kynurenic acid concentrations were normal. Different results were recorded from patients with OP with only a significant reduction in tryptophan and 3-hydroxyanthranilic acid when compared with healthy controls. During 6 months of treating the RA patients with prednisolone or methotrexate, and the OP patients with raloxifene or etidronate and calcium there were significant therapeutic responses and a significant trend towards a reduction in levels of neopterin in RA patients receiving methotrexate but no changes in the profiles of tryptophan metabolites. The results are consistent with the induction of indoleamine2,3-dioxygenase (IDO) in both RA and OP but with far greater activation of the pathway in the much more inflammatory condition, i.e. RA. It is concluded that there are changes in the kynurenine pathway, which may modify the activation of tissue glutamate receptors, in RA and OP, but that these are not affected by the drug treatments studied.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M. Feldmann, F.M. Brennan, R.N. Maini, Role of cytokine in rheumatoid arthritisAnn. Rev. Immunol. 14,397–440 (1996).
M.W. Taylor, G. Feng, Relationship between interferon-y, indoleamine-2,3-dioxygenase and tryptophan catabolismFASEB J. 5,2516–2522 (1991).
T.W. Stone, The neuropharmacology of quinolinic acid and kynurenic acidsPharmacol. Revs. 45,309–379 (1993).
T.W. Stone, Kynurenines in the CNS - from obscurity to therapeutic relevanceProgr. Neurobiol . 64185–218 (2001).
T.W. Stone, M.N. Perkins, Quinolinic acid: a potent endogenous excitant at amino acid receptors in the CNSEurop. J. Pharmacol. 72,411–412 (1981).
M.N. Perkins, T.W. Stone, An iontophoretic investigation of the action of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acidBrain Res. 247,184–187 (1983).
S.S. Gill, R.W. Mueller, R.F. McGuire, O.M. Pulido, Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicityToxicol. Pathol. 28,277–284 (2000).
D.J. Mason, L.J. Suva, P.G. Genever, A.J. Patton, S. Steuckle, R.A. Hillam, T.M. Skerry T.M., Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents?Bone 20,199–205 (1997).
A.J. Patton, P.G. Genever, M.A. Birch, L.J. Suva, T.M. Skerry, Expression of an NMDA type receptor by human and rat osteoblasts suggests a novel glutamate signalling pathway in boneBone 22,645–649 (1998).
C.L. Eastman, T.R. Guilarte, The role of hydrogen peroxide in the in vitro cytotoxicity of 3hydroxykynurenineNeurochem. Res. 151101–1107 (1990).
S. Okuda. N. Nishiyama, H. Saito, 11. Katsuki, Hydrogenperoxide-mediated neuronal cell death induced b an endogenous neurotoxin, 3-hydroxykynurenine,Proc. Nat. Acad. Sci (USA) 93,12553–12558 (1996).
S.R. Thomas, R. Stocker R., Redox reactions related to indoleamine-2,3-dioxygenase and tryptophan metabolism along the kynurenine pathwayRedox Report 4,199–220 (1999).
F.C. Amett, S.M. Edworth, D.A. Block, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, N.H. Liang, H.S. Lethra, T.A. Medsgar, D.M. Mitchell, D.H. Neustadt, R.S. Pinals, J.G. Schaller, J.T. Sharp, R.L. Wilder, G.G. Hunder, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritisArthritis Rheum. 31,315–324 (1988).
WHO, Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: technical report series 843, WHO, Geneva (1994).
M.P. Heyes, K. Saito, O. Devinsky, N.S. Nadi, Kynurenine pathway metabolites in CSF and serum in complex partial seizuresEpilepsia 35,251–257 (1994).
M. Huengsberg, I.B. Winer, M. Gompels, R. Round, J. Ross, M. Shahmanesh, Serum-to-kynurenine ratio increases with progressive disease in HIV-infected patientsClin. Chem.44, 858–862 (1998).
B. Widner, F. Leblhuber, J. Walli, G.P. Tilz, U. Demel, D. Fuchs, Tryptophan degradation and immune activation in Alzheimer’s diseaseJ. Neural Transco.107, 343–353 (2000).
B. Widner, N. Sepp, E. Kowald, U. Ortner, B. Wirleimer, P. Fritsch, G. Baier-Bitterlich, D. Fuchs, Enhanced tryptophan degradation in systemic lupus erythematosusImmunobiology201, 62I-630 (2000).
H. Kazda, N. Taylor, D. Healy, D. Walker, Maternal, umbilical and amniotic fluid concentrations of tryptophan and kynurenine after labor or cesarean sectionPediat. Res.44, 368–373 (1998).
K. Saito, S. Fujigaki, M.P. Heyes, K. Shibata, M. Takemura, H. Fujii, H. Wada, A. Noma, M. Seishima, Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiencyAmer. J. Physiol.279, F565–F572 (2000).
R.J. Truscott, A.J. Elderfield, Relationship between serum tryptophan and tryptophan metabolite levels after tryptophan ingestion in normal subjects and age-related cataract patientsClin. Sci.89, 591–599 (1995).
C. Nerve, P. Beyne, H. Jamault, E. Delacoux, Determination of tryptophan and its kynurenine pathway metabolites in human serum by HPLC with simultaneous UV and fluorimetric detectionJ. Chromatog.675, 157–161 (1996).
J.H. Flinn, J.M. Price, N. Yess, R.R. Brown, Excretion of tryptophan metabolites by patients with rheumatoid arthritisArthritis Rheum.7, 201–210 (1964).
I.M. Bett, Urinary tryptophan metabolites in rheumatoid arthritis and some other diseasesAnn. Rheum. Dis.25, 556–562 (1966)
R.S. Pinals, Tryptophan metabolism in rheumatic diseaseArthritis Rheum.7, 662–669 (1964).
H. Spiera, R. Vallarino, Serum kynurenine in rheumatoid arthritisJ. Clin. Invest.48, 856–859 (1969).
D. Labdarios, D.Y. McKenzie, J.W.T. Dickerson, D.V. Parke, Metabolic abnormalities of tryptophan and nicotinic acid in patients with rheumatoid arthritisRheumatol. Rehab.17, 227–232 (1978).
T. Igari, M. Tsuchizawa, T. Shimamura, Alteration of tryptophan metabolism in the synovial fluid of patients with rheumatoid arthritis and osteoarthritisTohoku J. Exp. Med.153, 79–86 (1987).
D.G. Malone, P.W. Dolan, R.R. Brown, M.V. Kalayoglu, R.A. Arend, G.I. Byrne, Y. Ozaki, Interferon-y induced production of IDO in cultured human synovial cellsJ. Rheumatol.21, 1011–1019 (1994).
A. Bertazzo, L. Punzi, N. Bertazzolo, M. Pianon, A. Pozzuoli, C.V.L. Costa, G. Allegri, Tryptophan catabolism in synovial fluids of various arthopathies and its relationship with inflammatory cytokinesAdv. Exp. Med. Biol.467, 565–570 (1999).
Z.Z. Altindag, G. Sahin, F. Inanici, Z. Hascelik, Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritisRheumatol. Intern.18, 107–1 11 (1998).
H.L. Nurcombe, R.C. Bucknall, S.W. Edwards, Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: priming and activation in vivoAnn.Rheum.Dis.50, 147–153 (1991).
M.L. Tiku, J.B. Liesch, F.M. Robertson, Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokinesJ. Immunol.145, 690–696 (1990).
D.R. Blake, N.D. Hall, D.A. Treby, B. Halliwell, J.M.C. Gutteridge, Protection against superoxide and hydrogen peroxide in synovial fluid from rheumatoid patientsClin. Sci.61, 483–486 (1981).
R. Miesel, M. Zuber, Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseasesInflammation17, 551–561 (1993).
H. Kaur, S.E. Edmonds, D.R. Blake, B. Halliwell, Hydroxyl radical generation by rheumatoid blood and knee joint synovial fluidAnn. Rheum. Dis.55, (supp): 915–920 (1996).
D.A. Rowley, J.M.C. Gutteridge, D.R. Blake, M. Farr, B. Halliwell, Lipid peroxidation in rheumatoid arthritis: thiobarbituric acid - reactive material and catatylic iron salts in. synovial fluid from rheumatoid patientsClin. Sci.66, 691–695 (1984).
M. Uesugi, T. Hayashi, H.E..lasin, Covalent cross-linking of immune complexes by oxygen radicals and nitriteJ. Immunol.161, 1422–1427 (1998).
M. Zuber, R. Miesel, Xanthine oxidase and sulthydryls and the antirheumatic action of xanthine oxidase inhibitor allopurinol in the animal model of collagen (1I) arthritisAktuelle Rheumatol.19,90–98 (1994).
R. Miesel, R. Hartung, H. Kroeger, Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseasesInflammation20,427–438 (1996).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Forrest, C.M., Kennedy, A., Stone, T.W., Stoy, N., Gail Darlington, L. (2003). Kynurenine and Neopterin Levels in Patients with Rheumatoid Arthritis and Osteoporosis During Drug Treatment. In: Allegri, G., Costa, C.V.L., Ragazzi, E., Steinhart, H., Varesio, L. (eds) Developments in Tryptophan and Serotonin Metabolism. Advances in Experimental Medicine and Biology, vol 527. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0135-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0135-0_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4939-6
Online ISBN: 978-1-4615-0135-0
eBook Packages: Springer Book Archive